CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the National Institute of Aging (NIA). Sirtris and its academic collaborators were awarded funding to study the effects of one of its new chemical entities (NCEs) on diseases of aging in mice. The NCE, which is structurally distinct from, and significantly more potent than Sirtris’ proprietary resveratrol product (SRT501), will be tested in aging mice.
